Table of Contents

ZYMOGENETICS INC filed this Form 10-Q on May 4, 2010.

Click on link to view section or document

Entire Document w/ attachment(s)

Entire Document (10-Q) PAGE 1. UNITED STATES PAGE 2. ZYMOGENETICS, INC. PAGE 3. PART I FINANCIAL INFORMATION PAGE 4. ZYMOGENETICS, INC. PAGE 5. N/A PAGE 6. N/A PAGE 7. N/A PAGE 8. N/A PAGE 9. N/A PAGE 10. N/A PAGE 11. N/A PAGE 12. N/A PAGE 13. N/A PAGE 14. Item 2. PAGE 15. - PAGE 16. Results of Operations PAGE 17. Bayer PAGE 18. Research and development PAGE 19. Selling, general and administrative PAGE 20. Other income (expense) PAGE 21. Cash flows from operating activities PAGE 22. Cash flows from investing activities PAGE 23. Contractual Obligations PAGE 24. Item 3. PAGE 25. PART II OTHER INFORMATION PAGE 26. We anticipate incurring additional losses and may not achieve profitability. PAGE 27. We are focused on a limited number of product candidates, and adverse developments with respect to o PAGE 28. N/A PAGE 29. Our success with RECOTHROM will depend on our ability to effectively compete with large and well est PAGE 30. N/A PAGE 31. N/A PAGE 32. Pending litigation by our primary competitor for RECOTHROM could have an adverse impact on our busin PAGE 33. Our patents may be unenforceable against infringers. PAGE 34. We may be unable to protect our trade secrets, which would enable others to compete more effectively PAGE 35. With the termination of the co-promotion arrangement with Bayer HealthCare as of the end of 2009, we PAGE 36. N/A PAGE 37. N/A PAGE 38. Failure to effectively manage the RECOTHROM supply chain could result in inventory shortages, supply PAGE 39. The failure to attract or retain key management or other personnel could decrease our ability to dis PAGE 40. If we use biological and hazardous materials in a manner that causes contamination or injury or viol PAGE 41. Risks Related to Our Industry PAGE 42. Risks Related to Ownership of Our Stock PAGE 43. N/A PAGE 44. N/A PAGE 45. Item 6. PAGE 46. SIGNATURE

Entire Document (EX-31.1) PAGE 1. Exhibit 31.1

Entire Document (EX-31.2) PAGE 1. Exhibit 31.2

Entire Document (EX-32.1) PAGE 1. Exhibit 32.1